Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) released its quarterly earnings data on Friday. The company reported $0.22 earnings per share for the quarter, Zacks reports. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.

Chugai Pharmaceutical Price Performance

Shares of CHGCY traded down $0.40 during trading hours on Friday, hitting $27.48. 63,620 shares of the company were exchanged, compared to its average volume of 204,659. The firm has a fifty day simple moving average of $28.98 and a 200-day simple moving average of $27.01. The company has a market capitalization of $90.44 billion, a PE ratio of 31.58 and a beta of 0.69. Chugai Pharmaceutical has a one year low of $19.50 and a one year high of $34.84.

Analyst Ratings Changes

CHGCY has been the subject of several research reports. Smbc Nikko Sec. raised Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.